Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Radiation to Immunotherapy May Extend PFS in Progressive Lung Cancer

Publish date:: October 22, 2019

Key clinical point: For patients with metastatic non–small cell lung cancer (NSCLC) who have disease progression on immunotherapy, adding stereotactic body radiotherapy (SBRT) could improve progression-free survival (PFS).

Major finding: The disease control rate was 57.14%.

Study details: A prospective phase 2 trial involving 56 patients with metastatic non–small cell lung cancer (NSCLC).

Disclosures: The investigators disclosed relationships with Genentech, AstraZeneca, Merck, and others.

Citation:

Campbell et al. ASTRO 2019. Abstract 74.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immunotherapy

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,

New registry focuses on rheumatic immune-related AEs of cancer therapy,

Tumor neoantigenicity metric improves prediction of response to immunotherapy,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,